Page 16 of 19 · 436 questions tagged vendor-vetting.
I have both a purity figure and a content figure, which is why the discrepancy is visible. I can parse the result. I am less sure what it licenses me to conclude. I…
The case in front of me: TFC · liraglutide. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I want to know whether…
Numbers first: 97.6% · orforglipron · GL Biochem. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum…
What I am working with: Medutest · ChinaPeptides (QYAOBIO). I would like help reading this properly rather than being told what conclusion to reach. I have the full…
I have both a purity figure and a content figure, which is why the discrepancy is visible. This is presented as though it settles something, and I am not convinced it…
The lot number on the vial matches the certificate, which at least rules out the easy problem. The figures are clear enough; the question is what they mean and what…
Stated plainly: 96.4% · a GLP-1 receptor agonist · HJ. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight,…
Numbers first: JEEP · dulaglutide. Before I write this off, I want to check whether it is a known failure mode. I have the lot number, the certificate and the date,…
I have certificates from two lots and an independent result on one of them. I want a method I can write down and repeat, not a rule of thumb. I would rather…
What I am working with: 98.2% · a GLP-1 receptor agonist · QST. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not…
Stated plainly: WXT · ChinaPeptides (QYAOBIO). I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
What I am working with: ERP · Nantong Guangyuan Chemical. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can…
The particulars: method section · CPC. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
Numbers first: JEEP · Bachem Holding (Suzhou). I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…
Setup, so nobody has to ask: 96.8% · mazdutide · Homopeptide. I am trying to build something sustainable rather than something thorough that I will abandon. I have…
What I have: SGN · orforglipron. Before I write this off, I want to check whether it is a known failure mode. I have the lot number, the certificate and the date, and…
The case in front of me: list of related substances · GL Biochem. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
Numbers first: WWB · Bachem Holding (Suzhou). I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
Numbers first: 98.4% · dulaglutide · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
I am comparing a supplier certificate against an independent result on the same lot. I would like to know the limits of what can be inferred from this. What I am…
Details up front: 98.2% · dulaglutide · GGPeps. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which…
Details up front: mazdutide · lot-specific certificate. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
For reference: method section · Homopeptide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
For reference: date of analysis · QST. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…